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Background. Multimorbidity is common but little is known about its relationship with obstructive sleep apnea (OSA).
Methods. Men Androgen Inflammation Lifestyle Environment and Stress Study participants underwent polysomnography.
Chronic diseases (CDs) were determined by biomedical measurement (diabetes, dyslipidaemia, hypertension, obesity), or
self-report (depression, asthma, cardiovascular disease, arthritis). Associations between CD count, multimorbidity,
apnea-hyponea index (AHI) and OSA severity and quality-of-life (QoL; mental & physical component scores), were
determined using multinomial regression analyses, after adjustment for age.
Results. Of the 743 men participating in the study, overall 58% had multimorbidity (2+ CDs), and 52% had OSA (11%
severe). About 70% of those with multimorbidity had undiagnosed OSA. Multimorbidity was associated with AHI and
undiagnosed OSA. Elevated CD count was associated with higher AHI value and increased OSA severity.
Conclusion. We demonstrate an independent association between the presence of OSA and multimorbidity in this
representative sample of community-based men. This effect was strongest in men with moderate to severe OSA and
three or more CDs, and appeared to produce a greater reduction in QoL when both conditions were present together.
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Introduction
Obstructive sleep apnea (OSA) is defined as the cessation of
naso-buccal air flow for more than 10 s [1] and is diagnosed
based on the apnea-hypopnea index (AHI) [2]. A systematic
review [3] showed the impaired quality of life (QoL) in OSA
patients when compared with population norms. Severe
OSA has also been demonstrated to increase all-cause mor-
tality [4]. Risk factors for OSA include ageing, elevated Body
Mass Index (BMI) and male gender [5, 6]. Aside from the
well-known relationship with obesity, OSA has been previ-
ously reported to be associated with hypertension [7], car-
diovascular disease (CVD) [7, 8], diabetes [9, 10], chronic
obstructive pulmonary disease [11] and depression [11].
Multimorbidity, or the presence of two or more medical
conditions in an individual [12], has a high prevalence in
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numerous populations [13–15]. Multimorbidity prevalence
increases with age [14, 16] and social deprivation [16, 17],
and is associated with increased medical consultations, pre-
scriptions, emergency hospital utilisation, hospital length of
stay and mortality rates [18–20]. The relationship between
the presence of OSA and the development of multimorbidity
and the subsequent impact on QoL remains unclear [11, 21].
This is complicated by the fact that OSA remains a severely
under-diagnosed condition, particularly in middle-aged to eld-
erly men. Recent estimates suggest approximately 75–80% of
OSA cases may be undiagnosed [22, 23] thereby limiting any
understanding of the true association between OSA and
chronic disease burden. High multimorbidity has been previ-
ously demonstrated in men with severe but not moderate or
mild OSA [21] among a primary care population referred to
a sleep laboratory for further evaluation. To the best of our
knowledge, there is no information on the relationship
between multimorbidity and OSA among the general popula-
tion. Consequently, our aim was to examine whether there is
an independent association between the presence and severity
ofOSA andmultimorbidity, and subsequent impacts onQoL, in
a community-based cohort of middle-aged to elderly men.
Methods
Study design
The Men Androgen Inflammation Lifestyle Environment and
Stress (MAILES) Study comprises randomly selected urban
community-dwelling men from South Australia aged 35
years at the time of enrolment [24]. Initial random sample
selection was by Electronic White Pages and recruitment
by computer-assisted telephone interviews (CATI) occurred
in 1999–2005. Biomedical, health, lifestyle and behavioural
assessment was conducted in two hospital-based clinics at
baseline and follow-up (2008–10), using standardised and
reproducible study protocols including anthropometry. Of
the 2038 participants at follow-up, 1445 without previously
diagnosed OSA were invited to participate in a sleep substudy
with 75.2% agreeing. Of these, a random sample of 1000 men
was chosen for inclusion and by the end of the study period,
837 successfully underwent polysomnography (PSG). For the
current analysis, we excluded men with incomplete informa-
tion for any CD leading to a total of 743 men (Fig. 1).
Previous analyses have demonstrated that the 837 men
who participated in the MAILES sleep study were broadly
representative of the target population [24]. An additional
analysis of these men and the current analytic sample, demon-
strated comparability across age group, education, region of
birth, marital status, with the current analytic sample have a
slightly higher proportion of men from higher income house-
holds and retirees (data not shown).
The study was approved by Queen Elizabeth and
the Royal Adelaide Hospital Human Research Ethics
Committees (HREC) and written consent were obtained.
Obstructive sleep apnea
In 2010–2011, subjects without a previous OSA diagnosis
underwent 8-channel in-home unattended PSG (Embletta
X100, Embla Systems, Colorado) which measured Electro-
encephalogram (EEG), Electroculogram, Electromyogram,
nasal pressure, thoracic and abdominal effort, oximetry,
body position, and limb movements. Trained staff visited
study participants in their homes to set-up and attach the
sleep study equipment, and measure neck circumference.
Failed studies were repeated if possible. A single experi-
enced sleep technician performed manual scoring of all
home PSGs according to the 2007 American Academy of
Sleep Medicine (AASM) (alternate) criteria [25]. An apnea
was defined as cessations of nasal flow lasting ⩾10 s, and
hypopneas as a >50% decrease in nasal flow (or in both
thoracic and abdominal excursions) and associated ⩾3%
oxygen desaturation or an EEG arousal. OSA was defined
as an AHI ⩾10/h. Prior work suggests an AHI of 5/h used
to define sleep-disordered breathing in the Wisconsin
study [2] is approximately equivalent to an AHI of 10/h
using the alternate AASM definition [26]. The Epworth
Sleepiness Scale [27], Pittsburgh Sleep Quality Index [28]
and the STOP questionnaire [29] were administered at the
time of the PSG.
Multi-morbidity and chronic disease assessments
Multimorbidity was defined as per [12] as the concurrent
presence of two or more of the following nine conditions
assessed at study follow-up clinics (2008–10): asthma,
heart disease, diabetes, depression, hyperlipidemia, hyper-
tension, obesity, osteoarthritis and rheumatoid arthritis.
Depression, diabetes, hyperlipidemia, hypertension and
obesity were determined during the clinic visit (see [30]
for an overview). Height was measured to the nearest 0.5
cm using a stadiometer, and weight to the nearest 0.1 kg
in light clothing and without shoes using standard digital
scales. BMI was calculated as weight (kg)/height (m)2.
Obesity was defined as a BMI ⩾30 kg/m2. A fasting blood
test was performed to determine total cholesterol and fast-
ing plasma glucose (FPG) levels. Men were deemed to have
diabetes if they self-reported having ever been told by a doc-
tor they had the condition, self-reported utilisation of glu-
cose-lowering drugs or by measurement at the clinic
(FPG⩾7.0 mmol/L) [31, 32]. Hyperlipidemia was defined as
total blood cholesterol ⩾5.5 mmol/L or self-report use of
cholesterol-lowering drugs [33]. Three blood pressure mea-
surements were taken 5–10 minutes apart using a standard,
calibrated blood pressure sphygmomanometer, while the
participant was relaxed and seated. The average of the
final two measures was used in the analyses. High blood
pressure was defined as systolic blood pressure⩾140 mm
Hg and/or diastolic blood pressure⩾90 mm Hg or the
self-reported use of drugs to lower blood pressure.
Depression status was determined using either a score
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over 15 for the Centre for Epidemiological Studies
Depression Scale [34] or a score over 13 for the Beck
Depression Index [35]. Participants self-reported if they
had ever been told by a doctor they had asthma, any
heart condition (including stroke), osteoarthritis or rheuma-
toid arthritis.
QoL assessment
Health-related QoL was assessed using the Short Form 36
questionnaire (SF-36) at study follow-up. The first general
health questions (SF1), as well as the mental and physical
component summary (MCS and PCS) domains, scored on
Australian normative data, were used in the analysis [36].
Physical and socio-demographic characteristics
Participants were interviewed by trained health workers
using a pre-coded questionnaire at study follow-up.
Individual-level variables included age, gender, marital status
and education level, household income, receiving govern-
ment benefits or pension and employment status. Detailed
demographic, biographical and risk factor information was
collected via a self-completed questionnaire.
Statistical analyses
Initial descriptive analyses were conducted to examine the
correlation between the outcome measure (multimorbidity;
expressed initially as the total number of CDs) and exposure
measure (OSA; expressed as continuous AHI), and selected
physical characteristics, socio-demographic factors, CD and
QoL status. Spearman correlation coefficients (rs) were cal-
culated to approximate the direction and degree of the
monotonic relationship between AHI and CD values, and
with the selected covariates. Participants were grouped
across the four exposure levels [absent/none (AHI<10),
mild (AHI ⩾10 and <20), moderate (AHI⩾20 and <30)
and severe (AHI⩾30)] to compare against the number of
CDs and QoL (PCS and MCS scores of the SF-36) using
the Kruskal–Wallis H test. Multinomial logistic regression
models for multimorbidity (2+ CDs vs 0–1 CD & 3+ CDs
vs 0–2 CDs) and QoL were then fitted across all exposure
levels (Absent, Mild, Moderate and Severe) to determine
crude, age-adjusted, and multi-adjusted odds ratios. Finally,
to test for any interaction between multimorbidity and
OSA on QoL, number of CDs, OSA severity categories
and their interaction terms were compared against the
PCS and MCS domains of the SF-36. (as measured by the
SF-1, MCS and PCS). Unless stated otherwise, standard
errors are presented in tables and standard deviation in
the text. Crude data are presented in tables and text. All
analyses were carried out using SPSS version 20.0 (SPSS,
Inc., Chicago, IL, USA) and a p < 0.05 was considered
significant.
Results
Table 1 describes the baseline physical and socio-
demographic characteristics of the 743 study participants.
The mean age of the cohort was 59 ± 11 years (mean age
± S.D.) and the range was between 41 and 87 years. The
mean BMI was 28.6 ± 2.6 kg/m2 and 44% of the cohort
were obese (BMI⩾30 kg/m2). Fifty-two percent of the
cohort had OSA as defined by an AHI value over 10.
AHI was shown to have a comparable, positive correl-
ation coefficient with multimorbidity status and CD count,
as with neck circumference and age; both recognised risk
factors for OSA. CD count and AHI were both negatively
correlated with general QoL and the PCS domain of the
SF-36, and to a lesser degree the MCS, with CD count dem-
onstrating a significantly stronger correlation with all mea-
sures QoL indices. AHI and number of CDs also showed
a positive correlation between work and smoking status
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and negative correlation with income status (with higher CD
count additionally associated with lower education status)
(Table 2).
Among those with OSA, 52, 27 and 21% of the population
had mild (AHI⩾10 and <20), moderate (AHI⩾20 and <30)
and severe (AHI⩾30) OSA, respectively. The mean number
of CDs increased progressively for those with mild and
moderate OSA severity and plateaued thereafter (Fig. 2,
panel A). Overall, men in the severe group had 0.78 more
CDs [95% CI (0.42–1.14)] than those without OSA (p⩽
0.001 in the fully adjusted model). AHI was 9.4 events per
hour higher in those with three or more CDs than those
without any CD (p⩽ 0.001).
Among the 743 men included, 58% of the population had
multimorbidity. The proportion of those with multimorbid-
ity was higher in those with OSA than in those without (67%
v. 48%, p⩽ 0.001). There was no significant difference in
multimorbidity proportion between the mild, moderate
and severe groups, although the mean number of CDs
was significantly higher in the moderate and severe groups
when compared with the mild severity group (Fig. 2).
However, when the moderate and severe groups were
pooled, the proportion of those with three CDs in this
group was 12% higher (p⩽ 0.05) than those in the mild
group, suggesting that those with three CDs have a major
impact on the relationship between multimorbidity and
the severity of OSA. Among individual CDs, the proportions
of hypertension, obesity, diabetes and CVD were 22% (p⩽
0.05), 28% (p⩽ 0.05), 8% (p⩽ 0.05) and 10% (p⩽ 0.05)
higher in those with moderate or severe OSA than in
those without OSA. The proportions of those with hyper-
tension and depression were 14% (p⩽ 0.05) and 7% (p⩽
0.05) higher in those with mild OSA than in those without












Bachelor degree or higher 112 (15)
Occupation
Full time employed 416 (56)
Part time/casual employment 61 (8)
Retired 217 (29)
Unemployed 13 (2)
Home duties/student/other/not stated 31 (4)
Annual Income (Australian $)
Up to $ 12 000 15 (2)
$ 12 001–$ 20 000 50 (7)
$ 20 001–$ 40 000 149 (20)
$ 40 001–$ 60 000 153 (21)
$ 60 001–$ 80 000 107 (14)
Over $ 80, 000 232 (31)
Not stated 37 (5)
Marital status
Married/living with partner 592 (80)
Separated/divorced 74 (10)
Widowed 31 (4)
Never married 43 (6)
Not stated 3 (0)
BMI status
Underweight/normal (−25) 186 (25)
Overweight (25–29) 230 (31)
Obese I (30–34) 195 (26)
Obese II+ (35+) 132 (18)
Physical activity
Sedentary 171 (23)
Low activity 314 (42)
Moderate activity 188 (25)
High activity 62 (8)




Table 2. Bivariate associations between AHI and chronic disease count
and physical, social, quality of life and sleep questionnaire
AHI CD Count
R* p value R* p value
Multimorbidity
Multimorbidity status 0.22 p⩽ 0.001 NA NA
CD count 0.26 p⩽ 0.001 NA NA
Physical characteristics
Neck circumference 0.27 p⩽ 0.001 0.37 p⩽ 0.001
Age 0.20 p⩽ 0.001 0.21 p⩽ 0.001
Social characteristics
Work status 0.18 p⩽ 0.001 0.14 p⩽ 0.001
Smoking status 0.08 p⩽ 0.05 0.07 p⩽ 0.05
Marital status 0.02 ns 0.07 NS
Physical activity −0.01 ns 0.02 NS
Education −0.06 ns −0.11 p⩽ 0.05
Income status −0.11 p⩽ 0.005 −0.13 p⩽ 0.001
Quality of life (SF−36)
General health status
(SF1:1–5)
−0.12 p⩽ 0.001 −0.25 p⩽ 0.001
Physical component
summary (PCS)
−0.10 p⩽ 0.005 −0.24 p⩽ 0.001
Mental component
summary (MCS)
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the disease. Obesity was the only CD for which there was a
significant difference between the mild and the moderate/
severe group (+20%, p⩽ 0.05). There was also a detrimental
impact of OSA on both the PCS (p⩽ 0.0001) and MCS (p⩽
0.05) summary scores of QoL but only at a severe OSA
level.
Odds ratios for OSA severity status were examined
according to the presence of multimorbidity (Table 3).
When compared with those without, those with multimor-
bidity were more likely to have mild, moderate or severe
OSA than not having OSA. More precisely, the unadjusted
odds ratios of having mild, moderate or severe OSA were
1.91 (1.34–2.72), 2.92 (1.80–4.73) and 2.52 (1.51–4.21),
respectively, when compared with those without OSA.
The odds ratios for those with more than three CDs
were 3.27 (1.47–7.29), 5.11 (2.17–12.04) and 6.59 (2.78–
15.64) for the mild, moderate and severe OSA groups
when compared with those without OSA. The odds ratio
of having fair or lower health status was also significantly
higher in those with severe OSA than in those without
the condition [3.20 (1.72–5.93)].
The interaction between multimorbidity and OSA sever-
ity status was significant for both the PCS and the MCS QoL
measures (Fig. 3). For those with two or less CDs, there
were no significant differences between OSA groups in
both PCS and MCS mean values. However, in those with
three or more CDs, PCS significantly decreased with OSA
severity from 0.38 SD for mild to 0.68 SD for moderate/
severe groups (p⩽ 0.05 for moderate/severe v. mild). In
contrast, there was a significant 0.50 SD decrease in MCS
score in those with OSA, independently of the severity,
than in those without. In the MCS model, while the inter-
action between OSA and multimorbidity was significant (p
⩽ 0.05), the effect of OSA status alone was not (p = ns) in
opposition to the effect of multimorbidity (p⩽ 0.001). A
similar relationship as for MCS was found in those with
three CDs for general health status (SF1).
Discussion
The present study contributes to the understanding of the
relationship between multimorbidity and OSA severity in
previously undiagnosed men. More precisely, this study
reports that in men over 40 years old without a prior
OSA diagnosis, (1) multimorbidity is associated with OSA;
(2) the association between multimorbidity and OSA sever-
ity is more important in those with more than three CDs;
and (3) a detrimental interaction between multimorbidity
and OSA on QoL was found and was associated with
OSA severity in PCS.
A previous study investigated the relationship between
OSA and multimorbidity, as measured by CD count and
the disease burden multimorbidity assessment (DBMA), a
composite index taking into account the self-reported pres-
ence and burden of different CDs in patients who had
undergone PSG following referral by a physician [21].
Supportive of the results of the present study, Robichaud-
Halle et al. reported an association between multimorbidity
(DBMA) and severe OSA only [21]. The mean CD count
was not significantly different between OSA severity status,
which is in contrast to our findings of a progressively signifi-
cant increase in the number of CDs through OSA severity
status. A major difference and a strength of the present
study is that it explored previously undiagnosed OSA
cases, which represent the majority of those with OSA
[37]. While the referral/diagnostic bias (OSA suspicion v.
undiagnosed) could explain discrepancies, other differences
such as the number of CDs and AHI cut-off should be
acknowledged. Also, the AHI cut-off used to classify severity
Fig. 2. Relationship between obstructive sleep apnea severity
and the mean number of chronic disease and PCS and MCS SF-36
score in the 743 men. 1, 2 and 3, significantly different from the
absent, mild and moderate severity group, respectively. Data are
adjusted for age, sedentary lifestyle, marital, gross income,
working and smoking status.
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status in the Robichaud-Halle study was based on the 3%
desaturation criteria to define hyponeas with OSA defined
by an AHI ⩾5 while the present study used 3% and AHI
⩾10. Notwithstanding, they are roughly equivalent accord-
ing to the Rheuland study [26] which was adopted by the
AASM and has been shown to be associated with worst car-
diovascular outcomes [26, 38, 39].
Another important finding of the present study is that
while multimorbidity is associated with undiagnosed OSA,
those with exactly two CDs are not at an increased risk
of OSA. The proportion of those with three or more
CDs increased with positive OSA status but also with sever-
ity status making the use of three CDs a more interesting
cut-off than the two CDs generally used in multimorbidity
to investigate OSA status but also severity as previously sug-
gested [14].
The present results support the detrimental impact of
multimorbidity [40] and OSA [41] on QoL. The potential
relationship between OSA and multimorbidity on QoL
was previously suggested but not assessed [21]. To the
best of our knowledge, this study is the first to report a det-
rimental significant interaction effect between multimorbid-
ity and OSA on QoL as measured by the SF-36 summary
component scores. The impact of OSA was limited in
those with two or less CDs although it became very import-
ant in those with more than three CDs. In this group, the
presence of even mild OSA had an important detrimental
impact on both the MCS and PCS scores. Interestingly, for
PCS, the detrimental impact of OSA increased with its
severity but this was not the case for MCS. In those with
more than three CDs, the presence of undiagnosed OSA,
even with mild severity, has an important impact on their
QoL. Therefore OSA may be particularly important to iden-
tify in this population as, in clinical trials, continuous positive
airway pressure (CPAP) therapy had a beneficial impact on
PCS and MCS in most studies [42–44] but not all [45].
In a recent meta-analysis, an important bias noticed in the
majority of analysed studies on OSA is that cohorts are
mostly composed of patients tested on clinical suspicion of
OSA and that information on undiagnosed cases are lacking
[37]. The present study directly addresses this knowledge
gap by investigating this population. Potential bias from
those not participating in the study is possible but most
likely accounted for by the relatively high proportion of eli-
gible participants taking part in the PSG testing (59%). This is
particularly important when considering that OSA is a con-
dition with high undiagnosed rates and its timely treatment,
could improve the management of other CDs [46] and
improve health and QoL outcomes [38, 39, 47].
Strengths of the study include information on OSA sever-
ity (AHI), rather than OSA status and our large population
(n = 743). This study has some limitations. While data have
been adjusted for many risk factors, some potential residual
confounders could still not be taken into account. The num-
ber of CDs investigated in the present study (9) is relatively
small when compared with some other multimorbidity stud-
ies [14] and future studies should include a higher number of
CDs. In addition, not including men with incomplete details
Table 3. Differences in proportions of the participants and estimated odds ratios between OSA severity categories for multimorbidity, quality of life,
sleepiness and sleep quality and estimated OSA risk
OSA status Model
Absent Mild Moderate Severe Unadjusted
Adjusted for
age & social
N 360 199 102 82
Multimorbidity (2+) v. no (0–1) p⩽ 0.001 p⩽ 0.001
Proportion 2+ (n (%)) 171 (48) 126 (63)a 74 (72)a 57 (70)a
Odds Ratio* 1 1.72 2.68 2.02
(95% CI) (1.19–2.72) (1.63–4.42) (1.19–3.44)
3+ chronic diseases v. less (0–2) p⩽ 0.001 p⩽ 0.001
Proportion 3+ [n (%)] 69 (19) 57 (29) 40 (39)a 35 (43)a
Odds Ratio* 1 2.88 4.11 4.53
(95% CI) (1.27–6.48) (1.71–9.85) (1.82–11.30)
Quality of life
Fair/poor (4+) v. good or better (3−) p⩽ 0.005 p⩽ 0.005
Proportion fair/poor [n (%)] 33 (9) 26 (13) 14 (14) 20 (24)a
Odds Ratio* 1 1.62 1.60 3.46
(95% CI) (0.92–1.62) (0.80–3.22) (1.79–6.70)
*Odds ratios are presented from the adjusted model.
a Significantly different from the group without OSA in unadjusted model.
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on their CDs could have introduced bias. However, the
diagnosis of most of the CDs used in the study is based
on biomedical measurement or validated questionnaires
which are more precise than most other data sources
since it permits accounting for undiagnosed conditions
which have been previously shown to be high for some
CDs [48].
In summary, to the best of our knowledge, this study is
the first to report an association between multimorbidity
and OSA in a population of middle-aged to elderly men
with undiagnosed OSA. This study also demonstrated that
undiagnosed OSA has a major detrimental impact on the
QoL of people with multimorbidity. Our data suggest that
primary care physicians who treat men with multiple,
chronic conditions should investigate the presence of OSA
given its high rate of under diagnosis in the community
and additional synergistic QoL burden.
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